BiomX Ltd - Rega saham PHGE

BiomX Inc. (PHGE) is currently in the clinical trial stage, developing treatments for antibiotic-resistant bacteria, including therapy for cystic fibrosis. The operating model relies on external contractors for drug manufacturing and testing, as well as partner marketing. The current metric stands at 1.84. Serving as a valuation tool, this chart illustrates the dynamics of a company developing a closed-loop treatment system through unique bacteriophage cocktails.

The price reflects the market consensus on the value of the equity share, consolidating investor expectations into a single numerical expression through the mechanism of supply and demand. This daily price action visualizes the market's reaction to the efficiency of the bacteriophage modification platform, where the increase in value confirms the scalability potential of BiomX Inc. (PHGE) intellectual property in the fight against resistant infections.